What is HC Wainwright’s Estimate for OmniAb Q2 Earnings?

OmniAb, Inc. (NASDAQ:OABI) – Stock analysts at HC Wainwright cut their Q2 2026 EPS estimates for shares of OmniAb in a research note issued to investors on Friday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.10) for the quarter, down from their prior forecast of ($0.09). The consensus estimate for OmniAb’s current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for OmniAb’s Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.38) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at ($0.09) EPS.

Several other research firms have also commented on OABI. Benchmark reaffirmed a “buy” rating on shares of OmniAb in a research report on Friday, March 6th. Weiss Ratings lowered shares of OmniAb from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Finally, Wall Street Zen raised shares of OmniAb from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, OmniAb has an average rating of “Hold” and an average target price of $3.00.

OmniAb Stock Up 0.6%

NASDAQ OABI opened at $1.67 on Tuesday. OmniAb has a 52 week low of $1.22 and a 52 week high of $2.30. The firm has a market capitalization of $241.78 million, a P/E ratio of -3.63 and a beta of 0.07. The company has a 50-day moving average price of $1.63 and a 200-day moving average price of $1.73.

OmniAb (NASDAQ:OABI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04. OmniAb had a negative net margin of 187.59% and a negative return on equity of 20.31%. The firm had revenue of $14.43 million during the quarter, compared to analyst estimates of $5.60 million.

Insider Transactions at OmniAb

In other OmniAb news, CEO Matthew W. Foehr sold 19,244 shares of the stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $1.49, for a total transaction of $28,673.56. Following the completion of the sale, the chief executive officer directly owned 4,420,492 shares of the company’s stock, valued at $6,586,533.08. This trade represents a 0.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 117,703 shares of company stock worth $193,597. Company insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its holdings in shares of OmniAb by 20.5% in the second quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock valued at $78,000 after purchasing an additional 7,624 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of OmniAb by 6.0% in the second quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock valued at $280,000 after purchasing an additional 9,163 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after purchasing an additional 9,716 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of OmniAb in the first quarter valued at $25,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of OmniAb by 92.5% in the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after purchasing an additional 10,438 shares in the last quarter. 72.08% of the stock is owned by hedge funds and other institutional investors.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.